Cancer Genetics has reported its Q3 strategic, financial and operating results for the third quarter ended September 30, 2019.
The company announced it has started dosing patients in its Phase 1 clinical trial of SB 11295 in patients with...
The company announced the pricing of US$50 million aggregate principal amount of 5.25 percent convertible senior notes due 2024.
Relevium Technologies Inc. (TSXV:RLV, OTCQB:RLLVF) is pleased to announce the launch of LeefyLyfeTM Organics.
Cardiol Therapeutics Inc. is pleased to announce the formation of the Clinical Steering Committee for a Phase 2 international trial.
Enlivex Therapeutics' Phase 1b clinical trial is evaluating the company's Allocetra in patients with severe sepsis.
Avricore Health Inc. and the Ontario Pharmacists Association are pleased to announce a Memorandum of Understanding.